Catalog No.
YVV22401
Expression system
E. coli
Species
Lassa virus (strain Mouse/Sierra Leone/Josiah/1976) (LASV)
Protein length
Gly2-Pro99
Predicted molecular weight
22.89 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
O73557
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
RING finger protein Z, Protein Z, Zinc-binding protein, Z
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816
Detection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon., PMID:40296141
Mapping the antibody response to Lassa virus vaccination of non-human primates., PMID:40168843
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130
Lassa virus protein-protein interactions as mediators of Lassa fever pathogenesis., PMID:40022100
Recombinant Pichinde reporter virus as a safe and suitable surrogate for high-throughput antiviral screening against highly pathogenic arenaviruses., PMID:39970958
The Lassa Virus Stable Signal Peptide Undergoes a Conformational Change to Aid Viral Fusion., PMID:39946735
C-reactive protein and association with disease severity in hospitalized adult patients with Lassa fever in Nigeria., PMID:39877415
Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses., PMID:39861906
Targeting n-myristoyltransferases promotes a pan-Mammarenavirus inhibition through the degradation of the Z matrix protein., PMID:39625987
Quantification of heterogeneity in human CD8+ T cell responses to vaccine antigens: an HLA-guided perspective., PMID:39624092
Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates., PMID:39605488
A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison., PMID:39512237
Lassa virus persistence with high viral titers following experimental infection in its natural reservoir host, Mastomys natalensis., PMID:39472431
Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study., PMID:39375602
Endosomal fusion of pH-dependent enveloped viruses requires ion channel TRPM7., PMID:39353909
Cellular N-Myristoyl Transferases Are Required for Mammarenavirus Multiplication., PMID:39339839
Intracellular lipid droplets are exploited by Junín virus in a nucleoprotein-dependent process., PMID:39292070
Characterization of bi-segmented and tri-segmented recombinant Pichinde virus particles., PMID:39264155
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses., PMID:39243373
Cellular N-myristoyl transferases Are Required for Mammarenavirus Multiplication., PMID:39211253
The structure of the Lujo virus spike complex., PMID:39169025
Simultaneous screening for selective SARS-CoV-2, Lassa, and Machupo virus entry inhibitors., PMID:39159824
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview., PMID:39144987
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex., PMID:39013466
Lassa virus Z protein hijacks the autophagy machinery for efficient transportation by interrupting CCT2-mediated cytoskeleton network formation., PMID:39007910
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse., PMID:38924060
Assignment of the Lassa virus transmembrane domain in the prefusion and postfusion states in detergent micelles., PMID:38916786
Strategies of rational and structure-driven vaccine design for Arenaviruses., PMID:38908736
Cellular endosomal potassium ion flux regulates arenavirus uncoating during virus entry., PMID:38874413
Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch., PMID:38851430
Identification of a macrocyclic compound targeting the lassa virus polymerase., PMID:38844175
Unraveling factors responsible for pathogenic differences in Lassa virus strains., PMID:38826374
Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entry., PMID:38809021
Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort., PMID:38801652
An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice., PMID:38767352
A novel BSL-2 Lassa virus reverse genetics system modelling the complete viral life cycle., PMID:38747061
Pathogenic and Apathogenic Strains of Lymphocytic Choriomeningitis Virus Have Distinct Entry and Innate Immune Activation Pathways., PMID:38675975
Protective Efficacy of Lyophilized Vesicular Stomatitis Virus-Based Vaccines in Animal Model., PMID:38666640
The underlying mechanisms of arenaviral entry through matriglycan., PMID:38516183
Spatio-temporal spread and evolution of Lassa virus in West Africa., PMID:38486143
MHC-I alleles mediate clearance and antibody response to the zoonotic Lassa virus in Mastomys rodent reservoirs., PMID:38421939
An atlas of gross and histologic lesions and immunohistochemical immunoreactivity during the temporal progression of aerosolized Lassa virus induced hemorrhagic fever in cynomolgus macaques., PMID:38404292
Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex., PMID:38370709
Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus., PMID:38280377
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial., PMID:38272046
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability., PMID:38177144
Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates., PMID:38164768
RNA to Rule Them All: Critical Steps in Lassa Virus Ribonucleoparticle Assembly and Recruitment., PMID:38104324
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens., PMID:37972669
For research use only. Not for human or drug use.
